NYSCI (The New York Hall of Science)

Rachel Haurwitz, is the co-founder, President, and CEO of Caribou Biosciences and co-founder of Intellia Therapeutics. She introduces herself as a CRISPR “old timer” as she has been working in the field of gene editing since 2007 and holds patents on multiple CRISPR-based technologies. Haurwitz talks about being part of a group of scientists who are working to bring gene research into the commercial world primarily in the field of developing medicines to fight cancer. She explains how CRISPR which stands for “clustered regular interspaced short palindromic repeats” has democratized gene editing and has game-changing implications for multiple industries and our way of life.